CRISPR Therapeutics (CRSP) Tops Q4 EPS by 88c

CRISPR Therapeutics (NASDAQ: CRSP) reported Q4 EPS of ($1.41), $0.88 better than the analyst estimate of ($2.29). Revenue for the quarter came in at $6 million versus the consensus estimate of $7.12 million.

For earnings history and earnings-related data on CRISPR Therapeutics (CRSP) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Huazhu Group Limited (HTHT) Tops Q2 EPS by 37c
• BitFuFu Inc. (FUFU) Misses Q2 EPS by 13c